Dr.BariatricHTX said:

I have been dealing with this for almost 2 years now, and what I have found is that individual respo

I respect Dr.BariatricHTX perspective but I think this oversimplifies things a bit. Re: Phase 3 trial enrollment guide — the effect size varies considerably by population.

I am not saying Dr.BariatricHTX wrong entirely — just that the picture is more nuanced than a blanket statement. The SURMOUNT data specifically shows baseline BMI-dependent responses.

Relevant to Phase 3 trial enrollment guide — here is my latest bloodwork comparison:

Key improvements: A1C 7.2% → 5.3%, triglycerides 195 → 95 mg/dL, hsCRP 6.0 → 1.3 mg/L. All on tirzepatide for 11 months.

The inflammatory marker drop is what impresses me most. Consistent with the SELECT trial's cardiovascular findings.

Thank you PharmHunterJen! This is incredibly helpful. Bookmarking for later. 🙏

Slightly tangential to Phase 3 trial enrollment but SandraNC_45 reminded me — has the insurance landscape changed recently?

I know it is not exactly on-topic but it seems related enough to ask here rather than starting a new thread. Apologies if this has been covered — I did search first.

Moderator note: Reminder: nothing posted here constitutes medical advice. Consult your healthcare provider.

Tagging this for the weekly digest. 👍